Coherus BioSciences, Inc. (CHRS)
$2.13
Rating:
Recommendation:
Buy
| Symbol | CHRS |
|---|---|
| Price | $2.13 |
| Beta | 0.865 |
| Volume Avg. | 4.44M |
| Market Cap | 237.205M |
| Shares () | - |
| 52 Week Range | 1.43-10.991 |
| 1y Target Est | - |
| DCF Unlevered | CHRS DCF -> | |
|---|---|---|
| DCF Levered | CHRS LDCF -> | |
| ROE | 139.21% | Strong Buy |
| ROA | -38.29% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -358.30% | Strong Sell |
| P/E | -0.84 | |
| P/B | -1.56 | Sell |
Latest CHRS news
About
Download (Excel)Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.